Skip to content
10-Q

Quarterly Report

Marker Therapeutics, Inc. MRKR

0001104659-26-062763

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 16.67M sh
Shares Diluted Q1 2026 · Mar 31, 2026 19.31M sh
Shares Diluted Q1 2026 · Mar 31, 2025 11.11M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.4M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$5.5M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $14.92M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $16.07M
Stockholders Equity Q1 2026 · Mar 31, 2026 $13.8M
Stockholders Equity Q1 2026 · Dec 31, 2025 $16.8M
Stockholders Equity Q1 2026 · Mar 31, 2025 $14.49M
Stockholders Equity Q1 2026 · Dec 31, 2024 $18.56M
Current Liabilities Q1 2026 · Mar 31, 2026 $3.64M
Current Liabilities Q1 2026 · Dec 31, 2025 $2.27M
Total Liabilities Q1 2026 · Mar 31, 2026 $3.64M
Total Liabilities Q1 2026 · Dec 31, 2025 $2.27M
Current Assets Q1 2026 · Mar 31, 2026 $17.43M
Current Assets Q1 2026 · Dec 31, 2025 $19.07M
Total Assets Q1 2026 · Mar 31, 2026 $17.43M
Total Assets Q1 2026 · Dec 31, 2025 $19.07M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.16
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.40
Eps Basic Q1 2026 · Mar 31, 2026 −$0.16
Eps Basic Q1 2026 · Mar 31, 2025 −$0.40
Sga Expense Q1 2026 · Mar 31, 2026 $1.23M
Sga Expense Q1 2026 · Mar 31, 2025 $1.37M
Rd Expense Q1 2026 · Mar 31, 2026 $2.84M
Rd Expense Q1 2026 · Mar 31, 2025 $3.14M
Net Income Q1 2026 · Mar 31, 2026 −$3.18M
Net Income Q1 2026 · Mar 31, 2025 −$4.45M
Operating Income Q1 2026 · Mar 31, 2026 −$4.07M
Operating Income restated Q1 2026 · Mar 31, 2025 −$4.96M